Literature DB >> 7805174

Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin.

K Omura1, T Misaki, T Hashimoto, E Kanehira, T Watanabe, F Ishida, Y Watanabe, T Shirasaka.   

Abstract

Both leucovorin (LV) and cisplatin (cis-dichlorodiammine platinum II, CDDP) act as modulators of 5-fluorouracil (5-FUra) by increasing the intracellular concentration of reduced folate. We measured intracellular folate levels following the administration of LV or cisplatin in tumor-bearing rats to determine the optimal schedules for their use as 5-FUra modulators. Donryu rats were inoculated with Yoshida sarcoma cells on the right flank. Seven days after tumor inoculation, the animals were injected with LV or CDDP. The kinetic and dose-related changes in intracellular folate concentration were analyzed by means of a binding assay. Folate levels in the tumor tissues were significantly higher than baseline 1 and 2 h after administration of LV and remained significantly high until 8 h after administration. Folate levels in the tumor tissues were significantly higher than baseline 1 and 2 h after cisplatin administration, then decreased to a rather low level 8 h after, and to a significantly lower level than baseline 24 h after administration. The folate levels in the tumor tissue increased in proportion to the dose of LV, but did not increase when the dose of cisplatin was increased from 1 mg/kg to 8 mg/kg. Repeat high-dose administration of LV and repeat low-dose administration of cisplatin are advocated when they are used as modulators of 5-FUra.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805174     DOI: 10.1007/BF00686545

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  5-Fluorouracil infusion and low-dose weekly cisplatin: an analysis of increased toxicity.

Authors:  J Jeske; R M Hansen; J A Libnoch; T Anderson
Journal:  Am J Clin Oncol       Date:  1990-12       Impact factor: 2.339

2.  [Treatment of advanced cancer of the alimentary tract with cisplatin and 5-fluorouracil (UFT)].

Authors:  K Omura; K Doden; Y Munemoto; K Kawakami; T Miyanaga; T Hashimoto; F Ishida; Y Watanabe
Journal:  Gan To Kagaku Ryoho       Date:  1992-05

3.  A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study.

Authors:  M J O'Connell
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

4.  Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

Authors:  S Fujii; K Ikenaka; M Fukushima; T Shirasaka
Journal:  Gan       Date:  1978-12

5.  Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

Authors:  N Kemeny; A Younes; K Seiter; D Kelsen; P Sammarco; L Adams; S Derby; P Murray; C Houston
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

6.  A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.

Authors:  L Panasci; J Ford; R Margolese
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.

Authors:  C P Spears; B G Gustavsson; M Berne; R Frösing; L Bernstein; A A Hayes
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

8.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.

Authors:  K J Scanlon; E M Newman; Y Lu; D G Priest
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.

Authors:  R Pazdur; J A Ajani; R Winn; J Bearden; R J Belt; S Pilat; R Hallinan; B Levin
Journal:  Cancer       Date:  1992-02-15       Impact factor: 6.860

10.  Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma.

Authors:  J A Ajani; M D Kanojia; A Y Bedikian; J K Korinek; S H Stein; E G Espinoza; G P Bodey
Journal:  Am J Clin Oncol       Date:  1985-02       Impact factor: 2.339

View more
  2 in total

Review 1.  Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.

Authors:  T Shirasaka; S Yamamitsu; A Tsuji; T Taguchi
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

2.  Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).

Authors:  Hironaga Satake; Masaaki Iwatsuki; Yoshikazu Uenosono; Takeshi Shiraishi; Hiroaki Tanioka; Hiroshi Saeki; Keishi Sugimachi; Dai Kitagawa; Mototsugu Shimokawa; Eiji Oki; Yasunori Emi; Yoshihiro Kakeji; Akihito Tsuji; Yoshito Akagi; Shoji Natsugoe; Hideo Baba; Yoshihiko Maehara
Journal:  Cancer Chemother Pharmacol       Date:  2016-12-10       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.